Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

Shots:

• WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel
• Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications
• Exelixis leverages WuXi Bio’s integrated technology platforms to develop ADC, bispecific, and certain other novel tumor-targeting biologics applications

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Exelixis